Search the Newsreel

Bristol Myers Squibb Hopes to Boost Drug Trials with NVIDIA Supercomputer

Bristol Myers Squibb (BMS) is set to become the first life sciences company to acquire NVIDIA's latest generation supercomputer, the NVIDIA DGX SuperPOD with AIDGX Vera Rubin NVL72 systems. This move deepens a three-year partnership between the two companies, aiming to accelerate drug discovery …

Bristol Myers Squibb (BMY) Stock Still Looks Cheap After Fresh AI Drug Discovery News

Bristol Myers Squibb (BMY) has seen a 42.2% return over the past year, with a Discounted Cash Flow (DCF) model suggesting its intrinsic value is significantly higher than its current share price, implying it's undervalued by 48.1%. The company's expansion into AI-driven drug discovery …

Bristow Group will publish Q2 results Aug. 4 before its Aug. 5 call

Bristow Group (NYSE: VTOL) announced it will release its second-quarter 2026 financial results after market close on Tuesday, August 4, 2026. A conference call to discuss these results is scheduled for Wednesday, August 5, 2026, at 10:00 a.m. ET. Investors can access a live …

Bristow Group Announces Second Quarter 2026 Earnings Call

Bristow Group (NYSE: VTOL) announced it will release its financial results for the second quarter of fiscal year 2026 on Thursday, August 8, 2025, after market close. The company will also host an investor conference call and webcast on Friday, August 9, 2025, at …

New Iza-bren Approvals Underscore China's Rising Role In Bispecific ADCs

New approvals for Biokin’s Iza-bren, a first-in-class EGFRxHER3 bispecific ADC, for advanced nasopharyngeal carcinoma and recurrent or metastatic esophageal squamous cell carcinoma, highlight China's growing influence in this field. Biokin aims for global commercialization, leveraging its first-mover advantage and partnership with Bristol Myers Squibb. …

Lazard Asset Management LLC Raises Stake in Bristol Myers Squibb Company $BMY

Lazard Asset Management LLC increased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 23.7% in the first quarter, now owning 1,924,036 shares valued at $116.69 million. Other institutional investors like Vanguard Group Inc., State Street Corp, and Geode Capital Management LLC also significantly …

Bristow Group (VTOL) to Release Earnings on Tuesday

Bristow Group Inc (VTOL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Bristow Group Inc (VTOL), focusing on its regional contributions. The data indicates that the UK is the largest revenue contributor, followed by International, Norway, US, and Nigeria. However, detailed financials for business segments and current fiscal years …

Bristol-Myers Squibb stock rating held at Market Perform by Raymond James

Raymond James reiterated a Market Perform rating on Bristol-Myers Squibb (NYSE:BMY), stating that recent ZEPHYR trial data for ML-007C-MA does not pose a risk to Cobenfy and confirms its strong position in schizophrenia treatment. The firm believes Cobenfy has a significant commercial and clinical …

Bristol Myers Squibb (NYSE:BMY) Reaches New 52-Week High - Should You Buy?

Bristol Myers Squibb (NYSE:BMY) recently hit a new 52-week high of $63.24, trading around $63.07, and has a market capitalization of approximately $128.1 billion. Analyst sentiment is mixed, with 8 buys, 10 holds, and 1 sell rating, and an average price target of $61.25, …

VTOL|Bristow Group Inc|Price:45.760|Chg%:+0.800

Bristol Myers Squibb launches Relopduo, its fixed-dose combination for skin cancer, in India

Bristol Myers Squibb (BMS) has launched Relopduo, a fixed-dose combination for unresectable or metastatic melanoma, in India. This drug, which combines nivolumab and relatlimab, is the first FDA-approved FDC of two immune checkpoint inhibitors. Priced at ₹2,99,900 per vial, it offers a new treatment …

Theo Ai Strengthens Governance With Appointment of Former Bristol Myers Squibb GC to Board

Theo Ai has appointed Sandra Leung, former Executive Vice President and General Counsel of Bristol Myers Squibb, to its Board of Directors, enhancing the company's governance and strategic direction. Leung's extensive experience in litigation, corporate governance, and risk management will help tailor Theo Ai's …

Theo Ai Appoints Former Bristol Myers Squibb General Counsel Sandra Leung to Board

Theo Ai has appointed Sandra Leung, former EVP and General Counsel of Bristol Myers Squibb, to its board of directors. Leung previously served on Theo Ai’s General Counsel Advisory Board and brings over 30 years of corporate legal experience, including expertise in litigation risk …

BMO reiterates Bristol-Myers Squibb stock rating on Cobenfy edge By Investing.com

BMO Capital has reiterated its Market Perform rating and $60.00 price target for Bristol-Myers Squibb (NYSE: BMY), citing the competitive advantage of its schizophrenia drug, Cobenfy. This follows a failed Phase 2 trial for a competing drug, ML-007C-MA, which did not meet statistical significance. …

Wall Street's Insights Into Key Metrics Ahead of Bristol Myers (BMY) Q2 Earnings

Wall Street analysts forecast that Bristol Myers Squibb (BMY) will report quarterly earnings of $1.59 per share in its upcoming release, pointing to a year-over-year increase of 8.9%. It is anticipated that revenues will amount to $11.67 billion, exhibiting a decrease of 4.9% compared …

Bristol-Myers Squibb stock hits 52-week high at 62.89 USD

Bristol-Myers Squibb (BMY) stock recently hit a new 52-week high of $62.89, trading at $62.95 with a market capitalization of $127.94 billion. The company has maintained dividend payments for 56 consecutive years, currently yielding 4.06%. This milestone follows the FDA's acceptance of their New …

Bristow Group Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

This article provides a detailed overview of Bristow Group Inc (VTOL), a provider of vertical flight solutions. It covers the company's business scope, financial data including market cap and P/E ratio, and lists key executives along with their shareholdings. The report also touches upon …

Bristow Group Inc Revenue Breakdown – SWB:ERG1

Bristow Group Inc (SWB:ERG1) generated 1.27 billion EUR in revenue last year. The majority of this revenue, 843.31 million EUR, came from its Offshore Energy Services segment. The United Kingdom was the largest regional contributor, accounting for 350.80 million EUR.

Bristol-Myers Squibb Company Revenue Breakdown – HAM:BRM

Bristol-Myers Squibb Company (HAM:BRM) generated €41.03 billion in revenue last year, primarily from its Innovative Medicines segment. This marks a decrease from the previous year's €46.66 billion. The United States was the largest contributor to revenue, accounting for €28.33 billion.

Bristow Group Inc (VTOL) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Bristow Group Inc (VTOL), highlighting its current earnings forecast score of 8.00 and an average price target of $45.00. Based on four analysts, the stock receives a "Buy" rating with a potential upside of 34.58%. The company's …

Bristol-Myers Squibb Company Celegne Contingent Value Revenue Breakdown – BOATS:CELG/R

This article provides a brief overview of Bristol-Myers Squibb Company's Celgene Contingent Value financials, specifically focusing on its revenue breakdown for the Innovative Medicines segment and geographical contributions. Last year, the company generated $48.19 billion USD from Innovative Medicines, with the largest portion, $33.28 …

BMY|Bristol-Myers Squibb Co|Kurs:64.715|Änderung %:+0.885

Bristow Group Inc (VTOL)

This article provides a brief overview of Bristow Group Inc. (VTOL) stock, including its current price, market performance, and key financial metrics. It shows the stock trading at $45.50, down 1.32%, and lists data such as its P/E ratio, market capitalization, and dividend yield. …

Bristol-Myers Squibb Expands Pipeline With New First-in-Human Trial for BMS-986533

Bristol-Myers Squibb (BMY) has initiated a first-in-human Phase 1 trial for BMS-986533, an oral drug, to evaluate its safety, pharmacokinetics, and dosing in healthy volunteers. This randomized, double-blind, placebo-controlled study includes multiple dosing schemes and assesses interactions with common medications. The trial, which began …

Oak Associates Ltd. OH Acquires New Position in Bristol Myers Squibb Company $BMY

Oak Associates Ltd. OH has acquired a new position in Bristol Myers Squibb Company, purchasing 131,790 shares valued at approximately $8.0 million during the first quarter. Bristol Myers Squibb reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, and announced a …

Bristol Myers Squibb Company $BMY Stake Raised by Sei Investments Co.

Sei Investments Co. increased its stake in Bristol Myers Squibb (NYSE:BMY) by 8.2% in the first quarter, bringing its total holdings to over 2.19 million shares valued at $133 million. Several other institutional investors also adjusted their positions in BMY. Analysts have a mixed …

BMY|Bristol-Myers Squibb Co|Price:63.745|Chg%:-1.095

Bristol Myers Squibb Takes Drugmaker Week Rank at 92.6% of Its Yearly Range

BMY added 5.5% in the latest week and led its US Drug Manufacturers - General group, but Sharemaestro Market Dynamics have not fully confirmed the move.

Consortium launches Project SEAN to advance electric aviation across Scotland's Highlands and Islands

A consortium has launched Project SEAN to further electric aviation in Scotland's Highlands and Islands. This initiative was reported as a key newswire event, particularly relevant to Bristow Group Inc. (VTOL), and was alerted to Quantisnow Plus members shortly after publication. The project aims …

Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts

Bristol Myers Squibb (BMY) saw a 1.05% gain, closing at $61.40, while the broader market declined. The stock has increased by 10.47% over the past month, outperforming both the Medical sector and the S&P 500. Analysts anticipate an 8.9% year-over-year earnings growth for its …

VTOL5129959 Bond Risk Profile

This article provides a risk profile for the Bristow Group Inc. 6.875% 01-MAR-2028 bond, identified by FINRA VTOL5129959. It offers an overview of the bond's characteristics, including coupon and redemption details, and highlights key metrics for assessing credit risk. The content indicates that the …

Scotland's Highlands to host 2027 electric aircraft flights

Bristow-led Project SEAN has secured £1.5 million from the UK Department for Transport to conduct electric aircraft demonstration flights across Scotland's Highlands and Islands starting in 2027. The three-month program will use BETA Technologies' ALIA CTOL (CX300) aircraft to gather operational data, assess infrastructure, …

DOL Brief Sides With Bristol-Myers in PRT Appeal

The U.S. Department of Labor filed an amicus brief supporting Bristol-Myers Squibb in an appeal, arguing that retirees lack Article III standing to sue over pension risk transfers if they continue to receive full benefits. This action, along with a similar brief for Lockheed …

Bristow Group Inc (VTOL) Stock Price & 30 Year Financial Data

This GuruFocus page provides 30-year financial data for Bristow Group Inc (NYSE: VTOL), including its stock price, market capitalization, enterprise value, and various financial ratios. It details growth rates for revenue, EPS, EBIT, EBITDA, and book value, along with tools for detailed financial analysis, …

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains

Bristol Myers Squibb Co. (BMY) shares rose by 1.23% on Thursday, closing at $61.51, despite a general market downturn where the S&P 500 and Dow Jones Industrial Average both fell. The stock, however, still underperformed compared to some competitors and ended 2.19% below its …